Investigator Global Assessment · atopic eczema
It is very uncertain whether summary of findings table ‐ NB‐UVB changes investigator Global Assessment compared with PUVA (very low certainty).
1 finding from 1 review
Investigator Global Assessment ‐ not measured · atopic eczema
The review found no eligible studies for this question.
1 finding from 1 review
Investigator Global Assessment · atopic eczema
Summary of findings table ‐ NB‐UVB may leads to higher investigator Global Assessment (short‐term) compared with placebo (low certainty).
1 finding from 1 review
Investigator Global Assessment ‐ not measured · atopic eczema
The review found no eligible studies for this question.
1 finding from 1 review
Common infections measured by clinical assessment over 28 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in common infections measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
Cancer · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in cancer measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
Mortality measured by clinical assessment over 12 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in mortality measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
Clinical relapse · relapsing multiple sclerosis
Rituximab as 'switching' may leads to lower relapse measured by clinical assessment over 12 months compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Common infections measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes common infections measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Cancer · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes cancer measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Mortality measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes mortality measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Clinical relapse · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in relapse measured by clinical assessment over 24 months compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events measured by clinical assessment over 12 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in serious adverse events measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
Self- or observational assessment of intraoperative distress/pain/acceptance of treatment during provision of LA: pain-related behaviour (any disruptive behaviour/sudden reaction/movement) · Children and adolescents having dental treatment under local anaesthetic without general anaesthesia
1 finding from 1 review
pain-related behaviour (any disruptive behaviour/sudden reaction/movement); 4 studies reported a benefit in using the wand while the remaining studies results suggested no difference between the 2 methods of delivering…
6 studies · 704 participants
Very low
Self- or observational assessment of intraoperative distress/pain/acceptance of treatment during provision of LA: anxiety/pain experience (VAS, higher scores indicate worsened anxiety) · Children and adolescents having dental treatment under local anaesthetic without general anaesthesia
Video modelling acclimatisation for LA may leads to lower self- or observational assessment of intraoperative… compared with oral hygiene video (low certainty).
1 finding from 1 review
Self- or observational assessment of intraoperative distress/pain/acceptance of treatment during provision of LA (SEM scale, distress) · Children and adolescents having dental treatment under local anaesthetic without general anaesthesia
1 finding from 1 review
No numeric data reported. Study authors reported lower distress values (SEM scale) for all categories in the combined counter-stimulation and distraction group; this difference was significant when compared to the…
1 study · 78 participants
Very low
Intraoperative pain · Children and adolescents having dental treatment under local anaesthetic without general anaesthesia
It is very uncertain whether hypnosis changes self- or observational assessment of intraoperative… compared with conventional treatment (very low certainty).
1 finding from 1 review
Intraoperative pain · Children and adolescents having dental treatment under local anaesthetic without general anaesthesia
It is very uncertain whether electrical counter-stimulation device (DentalVibe) changes self- or observational assessment of intraoperative… compared with conventional treatment (no stimulation) (very low certainty).
1 finding from 1 review
Self- or observational assessment of intraoperative distress/pain/acceptance of treatment during provision of LA: pain-related behaviour during LA (negative vs positive behaviour; Frankl Behaviour Rating Scale) · Children and adolescents having dental treatment under local anaesthetic without general anaesthesia
It is very uncertain whether audiovisual distraction changes self- or observational assessment of intraoperative… compared with conventional treatment (very low certainty).
1 finding from 1 review